Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid

Masashi Yanae, Shinichiro Fujimoto, Kaori Tane, Maki Tanioka, Kimiko Fujiwara, Masanobu Tsubaki, Yuzuru Yamazoe, Yoshiyuki Morishima, Yasutaka Chiba, Shintaro Takao, Yoshifumi Komoike, Junji Tsurutani, Kazuhiko Nakagawa, Shozo Nishida

Research output: Contribution to journalArticlepeer-review

10 Citations (Scopus)


Background Bone represents one of the most common sites to which breast cancer cells metastasize. Patients experience skeletal related adverse events (pathological fractures, spinal cord compressions, and irradiation for deteriorated pain on bone) even during treatment with zoledronic acid (ZA). Therefore, we conducted a retrospective cohort study to investigate the predictive factors for symptomatic skeletal events (SSEs) in bone-metastasized breast cancer (b-MBC) patients. Methods We retrospectively collected data on b-MBC patients treated with ZA. Patient characteristics, including age, subtype, the presence of non-bone lesions, the presence of multiple bone metastases at the commencement of ZA therapy, duration of ZA therapy, the time interval between breast cancer diagnosis and the initiation of ZA therapy, and type of systemic therapy, presence of previous SSE were analyzed using multivariable logistic regression analysis. Results The medical records of 183 patients were reviewed and 176 eligible patients were analyzed. The median age was 59 (range, 30–87) years. Eighty-seven patients were aged ≥60 years and 89 patients were aged < 60 years. The proportions of patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-positive disease were 81.8%, 63.1%, and 17.6%, respectively. Fifty-three patients had bone-only MBC at the commencement of ZA therapy. SSEs were observed in 42 patients. In the multivariable logistic regression analysis, bone-only MBC but not a breast cancer subtype was an independent risk factor for an SSE during ZA therapy (odds ratio: 3.878, 95% confidence interval: 1.647–9.481; p = 0.002). Conclusions Bone-only MBC patients are more likely to experience an SSE even after treatment with ZA.

Original languageEnglish
Pages (from-to)18-22
Number of pages5
JournalJournal of Bone Oncology
Publication statusPublished - Sept 2017
Externally publishedYes


  • Bone metastasis
  • Breast cancer
  • Retrospective cohort study
  • Symptomatic skeletal events
  • Zoledronic acid

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid'. Together they form a unique fingerprint.

Cite this